Achieve Life Sciences Highlights Innovations in Nicotine Cessation

Achieve Life Sciences Engages at Healthcare Conference

SEATTLE AND VANCOUVER, British Columbia — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a prominent player in the pharmaceutical industry, is focused on the development and commercialization of cytisinicline for nicotine dependence. The company is excited to announce its participation in the upcoming J.P. Morgan Healthcare Conference, attending from January 13-16. This event serves as a prime opportunity for Achieve to engage with investors and stakeholders regarding its innovative work.

Leadership Overview

During the conference, Rick Stewart, the Chief Executive Officer, alongside other senior management members, will present an in-depth overview of Achieve’s late-stage cytisinicline program. The presentation will cover key clinical milestones reached thus far and outline the strategic plans for the year ahead, particularly focusing on nicotine dependence treatments.

Clinical Trials Success

Achieve has made significant strides in its clinical programs, successfully completing two Phase 3 clinical trials involving over 1,600 participants who smoke combustible cigarettes. Additionally, they have conducted a Phase 2 clinical trial aimed at adults who use e-cigarettes and wish to quit. Impressively, Achieve anticipates submitting a New Drug Application (NDA) for cytisinicline in support of smoking cessation therapies by the second quarter of the year, with plans to initiate another Phase 3 clinical trial for e-cigarette cessation later in the year.

Scheduling Meetings

Those interested in scheduling a one-on-one meeting with Achieve Life Sciences during the conference can reach out to the Investor Relations team via email at ir@achievelifesciences.com.

About Achieve Life Sciences

Achieve Life Sciences is dedicated to tackling the serious issue of nicotine addiction globally. Through the development of cytisinicline, a treatment derived from plant alkaloids, Achieve brings hope to many battling addiction. Cytisinicline has shown promising results in both smoking and vaping cessation studies, positioning the company as a leader in nicotine dependence solutions.

Addressing the Smoking Epidemic

Currently, smoking remains a leading cause of preventable deaths worldwide, claiming over eight million lives annually. Achieve’s commitment to combating these statistics is evident, as they aim to provide effective alternatives for smokers looking to quit. Given that more than 87% of lung cancer deaths and significant percentages of pulmonary and heart disease deaths are linked to smoking, the need for effective cessation programs cannot be overstated.

The Role of Cytisinicline

Cytisinicline functions by binding to nicotinic acetylcholine receptors in the brain, which is essential for reducing nicotine cravings and withdrawal symptoms. As an investigational drug, it is being developed rigorously for its potential role in smoking and vaping cessation, filling a crucial gap in available treatments for nicotine addiction, especially within the e-cigarette market.

Future Opportunities

With over 11 million adult e-cigarette users in the United States, Achieve recognizes the vital need for specific cessation aids, which is why cytisinicline has received Breakthrough Therapy designation. This designation underscores the urgency and necessity of developing effective treatments in a market lacking FDA-approved solutions for nicotine e-cigarette cessation.

Conclusion

As Achieve Life Sciences prepares for its series of discussions during the J.P. Morgan Healthcare Conference, the spotlight will undoubtedly highlight its relentless pursuit to innovate and provide effective solutions for those struggling with nicotine addiction. The company’s strategic direction, alongside the promising clinical data for cytisinicline, aims to pave the way for a healthier future.

Frequently Asked Questions

What is Achieve Life Sciences known for?

Achieve Life Sciences is a pharmaceutical company focused on developing cytisinicline for the treatment of nicotine dependence.

What is cytisinicline?

Cytisinicline is a plant-based alkaloid being developed as a treatment for smoking and e-cigarette cessation.

When is Achieve Life Sciences participating in the conference?

The company will participate in the J.P. Morgan Healthcare Conference from January 13-16.

How can investors meet with Achieve Life Sciences?

Investors can schedule one-on-one meetings by contacting the Investor Relations team via email.

What progress has Achieve made in clinical trials?

Achieve has completed two Phase 3 trials for smoking cessation and is progressing towards an NDA submission.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.